Seribantumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Seribantumab
Accession Number
DB11857
Description

Seribantumab has been used in trials studying the treatment of NSCLC, Heregulin, Adenocarcinoma, Colorectal Cancer, and Solid Tumor Cancers, among others.

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
Not Available
External IDs
  • MM-121

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Seribantumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Seribantumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Seribantumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Seribantumab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Seribantumab.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Seribantumab.
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Seribantumab.
Asfotase alfaThe risk or severity of adverse effects can be increased when Asfotase alfa is combined with Seribantumab.
AtezolizumabThe risk or severity of adverse effects can be increased when Atezolizumab is combined with Seribantumab.
AvelumabThe risk or severity of adverse effects can be increased when Seribantumab is combined with Avelumab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Chemical Identifiers

UNII
1N3L70MDFX
CAS number
1334296-12-6

References

General References
Not Available
PubChem Substance
347911251
Wikipedia
Seribantumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentAdenocarcinomas / Carcinoma, Large Cell / Heregulin / Non-Small Cell Lung Carcinoma (NSCLC) / Squamous Cell Carcinoma (SCC)1
2CompletedTreatmentER Positive, Her2 Negative Breast Cancer Patients / Triple Negative Breast Cancer Patients1
2CompletedTreatmentFallopian Tube Cancer / Malignant Peritoneal Neoplasm / Ovarian Epithelial Cancer1
2CompletedTreatmentHer2 Negative Breast Cancer Patients1
2RecruitingTreatmentLocally Advanced Solid Tumors / Metastatic Solid Tumors1
2TerminatedTreatmentMetastatic Breast Cancer1
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentColorectal Cancers / Non-Small Cell Lung Carcinoma (NSCLC) / Other Tumors With EGFR Dependence / Squamous Cell Head and Neck Cancer / Triple Negative Breast Cancer (TNBC)1
1CompletedTreatmentLocally Advanced/Metastatic Her2 Non Overexpressing Breast Cancer / Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer / Primary Peritoneal Cancer or Endometrial Cancer1
1CompletedTreatmentSolid Tumor Cancers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on October 20, 2016 14:54 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates